Sunho Biologics 

Sunho Biologics, Inc. is a biopharmaceutical firm dedicated to discovering, advancing, and bringing to market biological therapies. These treatments are designed to influence the body's immune system, both its inherent and adaptive responses, thereby altering the immune microenvironment. Among its portfolio is IAH0968, a monoclonal antibody specifically engineered to enhance antibody-dependent cell-mediated cytotoxicity, currently undergoing Phase II clinical trials for the treatment of biliary tract carcinoma and colorectal cancer. The company also develops IAP0971 and IAE0972, a pair of immunocytokines that have successfully concluded Phase I clinical trials for various advanced solid tumors, notably non-small cell lung cancer and colorectal cancer. Sunho Biologics also boasts a robust pipeline of early-stage assets. These include IBB0979, an immunocytokine targeting solid tumors; IBC0966, a dual-action fusion protein (anti-PD-L1 antibody-signal regulatory protein) in clinical development, designed to elicit tumor-specific immune responses; IBD0333, aimed at tumor cells; IAN0982, another oncology candidate; and immunosuppressants ISH0988 and ISH0613, which are being explored for autoimmune conditions. Established in 2018, the company operates from its headquarters in Huzhou, China, and functions as a subsidiary of Sunho Wisdom Investments Limited.